^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | dactolisib (RTB101) (mTOR inhibitor, PI3K inhibitor) + GC-1118A (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts
Published date:
11/28/2019
Excerpt:
Taken together, the superior antitumor efficacy of GC1118 alone or in combination with PI3K/mTOR/AKT inhibitors shows great therapeutic potential for the treatment of KRAS-mutant mCRC with elevated ratios of high- to low-affinity EGFR ligands and PI3K-AKT pathway activation.
DOI:
10.3390/ijms20235894
